SiliconDev enters the capital of SirtLife: new nutrigenomics project ready

A strategic investment to develop an integrated platform in the fields of longevity, advanced nutraceutics, genetics and personalised medicine. These are the details of the transaction carried out by the SiliconDev group, led by Stefano Valore, which formalised its entry into the capital of the US-based SirtLife Corporation.

The move is part of a growing focus on prevention models based on the analysis of biological data and health pathways increasingly tailored to the individual.

SirtLife is active in the development of nutraceutical solutions aimed at cellular well-being and healthy longevity. Its research activities focus on biological processes such as oxidative stress, inflammation and cell metabolism.

Alongside this strand, the company aims to strengthen an infrastructure dedicated to predictive and preventive medicine, with the aim of integrating genetic information and biomarkers into more targeted prevention strategies.

'SiliconDev's entry into the capital of SirtLife Corporation represents a strategic step of great significance,' said Stefano Valore, emphasising the goal of 'contributing to the construction of a solid, credible and scientifically oriented platform, capable of integrating technology, prevention and personalised health in an international development perspective'.